Bladder Cancer Canada Now Accepting Research Grant Applications
Bladder Cancer Canada (BCC) is pleased to announce that we are now accepting applications for research grants specific to bladder cancer. We will fund two projects in the amount of $50,000 each with funds being distributed on or before September 1, 2020 and intended to be spent by September 1, 2021.
The purpose of this grant is to support the development of outstanding Canadian research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. Investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research.
Completed applications must be submitted electronically no later than March 31, 2020 to:
Bladder Cancer Canada
Chair, Medical Research Board, Dr. Peter Black
Incomplete or late applications will not be accepted.
Questions? email@example.com | 1-866-674-8889
2018/2019 Bladder Cancer Canada Grant Recipients
Twenty-five percent of patients with bladder cancer are diagnosed with muscle-invasive disease. These patients usually receive chemotherapy followed by surgery to remove the bladder. Up to 60% of tumours, however, do not respond to chemotherapy. This study aims to measure the abnormal biological pathways in bladder tumour tissue at the RNA and protein levels, and to identify the pathways responsible for resistance to chemotherapy. This approach will allow Dr. Black’s research team to identify mechanisms of resistance to chemotherapy and, in the future, test drugs that block the identified resistance pathways. If successful, this project will open the door to novel therapies to overcome chemo-resistance.
Pictured below (L-R): Gregg Morin, PhD (Head of Proteomics, BC Cancer Genome Sciences Centre); Lead Investigator – Peter Black, MD FRCSC (Professor, University of British Columbia); Josa Batista da Costa, MD (post-doc); Kenichiro Ikeda, MD PhD (post-doc)